As global biotech investment patterns shift, investors are turning their eyes to Asia-Pacific. While China remains a powerhouse, emerging hubs like Singapore and South Korea are quickly gaining attention for their political stability, strong IP protection, and innovation-friendly policies.
Why are APAC biotech markets suddenly so appealing to investors? And how are these emerging hubs reshaping the future of global biotech innovation?
On Wealth Tracker, Hongbin Jeong speaks to Fabio La Mola, Partner at Bain & Company, to find out more.

The Big Story: Asia is cutting work weeks, closing schools to save fuel - Should Singapore consider this too?
11:40

What’s Trending: There are two Katy Perrys…? And a GPS sent one fan to the wrong football game
16:45

Wealth Tracker: Where to invest now? Navigating oil shocks, rate risks and the AI boom
18:39